Levomepromazine (Sinogan) is a drug commonly used to help with symptoms related to heightened physiological activity and provide supportive therapeutic benefit in clinical settings marked by increased discomfort or tension.

Therapeutic Scope

This medication is relevant across domains where short-term symptomatic assistance is appropriate, commonly used for conditions characterized by periods of heightened symptoms such as schizophrenia, manic phases of bipolar disorder, and pronounced psychomotor agitation. It also serves as an important adjuvant in specialized contexts, including palliative care, to help manage challenging nausea and vomiting, and to provide support for chronic pain.

“It is applied in scenarios where symptoms create noticeable functional strain, helping to ease the overall burden of distressing manifestations.”

This use assists with maintaining functional stability when symptoms are more noticeable and helps patients cope more steadily with symptom fluctuations, especially those involving intense restlessness and pronounced insomnia.

Quick Fact: Support for Symptomatic Relief
Levomepromazine is applied across domains where additional symptomatic support is needed, primarily for behavioral agitation, multi-symptom relief in palliative settings, and tension-related sleep disturbances.

Eligibility Profile: Who Can and Cannot Use Sinogan (Levomepromazine)

Official regulatory information outlines clear conditions for the use of Sinogan, defining specific populations who must not take the medicine and those who require heightened caution.

Classification	Who is Included/Excluded
Contraindicated	Individuals with hypersensitivity to levomepromazine, a history of agranulocytosis, closed-angle glaucoma, risk of urinary retention, or severe CNS depression. Also contraindicated with conditions like bradycardia (<55 bpm) or certain metabolic abnormalities (e.g., hypokalaemia).
Restricted/Not Recommended	Children under 18 years (contraindicated for some oral uses), pregnant women, and breastfeeding mothers (safety not established). Use is discouraged for ambulant patients over 50 years unless hypotensive risk is assessed.
Use with Caution	Patients with pre-existing cardiac disease or conditions that prolong the QT interval must be closely monitored. Caution is also required for those with severe hepatic or renal impairment due to the risk of drug accumulation. Patients with Parkinson’s disease should generally avoid Sinogan.

Regulatory documents structure eligibility by establishing absolute contraindications to exclude the highest-risk individuals and implementing special warnings to guide cautious use in vulnerable groups, such as the elderly and those with major organ dysfunction.

Interactions with other medicines and products — official regulatory information for Sinogan

Official regulatory documentation identifies the potential for Levomepromazine to interact with co-administered substances through both pharmacokinetic and pharmacodynamic mechanisms. The strongest regulatory constraint is the classification of certain combinations as contraindicated.

Classification Detail	Regulatory Statement
Interaction Severity	Contraindicated (e.g., specific QTc-prolonging drugs, non-antiparkinsonian dopamine agonists, alcohol/narcotics leading to coma); Clinically Significant (e.g., CYP2D6 inhibition).
Interacting Categories	CNS Depressants, QTc-Prolonging Agents, Antihypertensive Agents, CYP Enzyme Substrates/Inducers, Antacids.

The pharmacokinetic profile of Levomepromazine includes the statement that it is a potent inhibitor of Cytochrome P450 2D6 (CYP2D6). This documented interaction may lead to increased plasma concentrations of other medicines primarily metabolized by this enzyme. Conversely, co-administration with CYP enzyme inducers (e.g., Carbamazepine, Barbiturates) may result in decreased Levomepromazine plasma concentrations.

Pharmacodynamic reinforcement is noted with substances that have central nervous system depressant effects, such as alcohol and opiates, which may intensify the action of Levomepromazine. The administration of aluminium-containing antacids may cause reduced absorption of Levomepromazine, a condition that necessitates the separation of their dosing to maintain intended exposure. Furthermore, the risk of QTc prolongation is documented to be exacerbated in the presence of Hypokalemia or Hypomagnesemia.

Sinogan, which is chlorpromazine, functions primarily as an antagonist at multiple G protein-coupled receptors (GPCRs) throughout the central nervous system. Its principal mechanism involves binding to and blocking the D2 dopamine receptor family. This antagonism inhibits the normal G i-protein-mediated signal transduction pathway, which typically leads to a decrease in adenylyl cyclase activity and subsequent reduction in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP). By blocking D2 receptors, Sinogan prevents the cascade that suppresses cAMP production, thus modulating dopaminergic transmission.

Simultaneously, the molecule exhibits antagonistic properties at various serotonin receptors (e.g., 5 -HT2 A, 5 -HT2 C), adrenergic receptors (e.g., alpha1 subtypes), and histamine H1 receptors. Antagonism of the 5 -HT2 A receptor, which typically couples to the G q protein, interferes with the pathway leading to the production of inositol triphosphate ( IP3) and diacylglycerol (DAG). System-level physiological modulation arises from this broad-spectrum receptor blockade, resulting in widespread modification of neurotransmitter-mediated signaling and overall central nervous system function.

How to Use Sinogan

Levomepromazine administration is determined by the patient’s clinical context, utilizing a range of dosage forms and routes. The medicine is available as oral tablets and oral solutions for managed use, alongside a sterile solution for injection to allow for intramuscular (IM), intravenous (IV), and continuous subcutaneous infusion (CSCI) administration.

Official Dosing and Frequency Patterns

Dosing patterns require careful titration and vary widely by scenario. For ambulatory adult psychiatric use, the initial daily oral dosage typically ranges from 25 to 50 mg and is administered in divided doses. For bedridden patients, the starting oral dosage may be 100 to 200 mg daily and can be gradually increased up to a maximum of 1 g if necessary. When administered orally, the total daily dose is frequently adjusted so that the largest portion is taken at bedtime. For acute parenteral use, doses generally range from 12.5 to 25 mg and may be repeated every 6 to 8 hours as needed.

Preparation and Population Adjustments

Parenteral administration involves specific preparation; for example, intravenous injection requires dilution with an equal volume of normal saline immediately prior to administration. The injectable solution must be protected from light to maintain stability. For older adults, a lower initial dosage should be used. Similarly, in the paediatric population, the total daily oral dosage is explicitly not to exceed 37.5 mg.

Sinogan: Recent Clinical Evidence

Sinogan (levomepromazine, also known as methotrimeprazine) is classified as a first-generation, low-potency antipsychotic medication. Research involving levomepromazine generally focuses on its use in specific psychiatric disorders and in the management of distressing symptoms in palliative care settings.

---

Clinical Evidence Overview

Primary Area of Investigation	Summary of Research Findings
Schizophrenia and Psychosis	Studies have compared levomepromazine against other typical and atypical antipsychotics. While limited data is available, some trials reported that levomepromazine was associated with a greater reduction in overall symptom severity scores (such as the PANSS Total score) when compared to chlorpromazine in one randomized controlled trial (RCT). However, other atypical agents, like risperidone, were observed to be associated with better global state scores in a separate small RCT.
Palliative Care Symptom Management	Levomepromazine is frequently used globally in palliative care to address symptoms such as intractable nausea, vomiting, severe delirium, and restlessness, particularly in end-of-life care. Multiple systematic reviews indicate that while the drug is widely adopted, the supporting evidence primarily consists of lower-level data, such as case reports and open series, rather than large-scale, prospective randomized controlled trials.

---

Safety and Comparative Observations

Comparative studies have noted differences in the side effect profiles. For instance, levomepromazine was observed to be associated with a lower risk of certain movement disorders, such as tremor, compared to haloperidol in one study. Conversely, it was observed to be associated with a higher incidence of hypotension (low blood pressure) and dizziness when compared to some other antipsychotic agents. The overall quantity and quality of evidence across all indications may be limited, and larger, more robust studies are warranted to confidently establish its clinical effects and safety profile in long-term treatment.

Common questions about Sinogan (FAQ)

Q: What is the main condition Sinogan is approved to treat?

Approved regulatory uses include the treatment of schizophrenia and other psychotic conditions. It is also approved for use as an adjuvant treatment in palliative care settings. In this context, it is used to help manage symptoms such as delirium, agitation, and confusion associated with pain.

Q: Is Sinogan the same as other medicines for psychosis?

Sinogan, with the active ingredient levomepromazine, is scientifically categorized within the Phenothiazine group of medicines, also known as first-generation antipsychotics. Regulatory documents indicate that while it belongs to a similar class, studies comparing it to specific agents have observed differences in their effects and side-effect profiles.

Q: Why is Sinogan used for more than one condition?

The wide range of uses is related to the drug's action on multiple systems in the central nervous system. Official information indicates that the drug possesses sedative, antiemetic (anti-nausea and vomiting), and analgesic (pain-relieving) properties. This broad action is understood to support its use for managing several different symptoms.

Q: Is there a generic version of Sinogan available?

Sinogan is the trade name for this medicine. The active ingredient, Levomepromazine (also called Methotrimeprazine), is available under its generic name from various manufacturers.

Q: Are there different strengths of Sinogan tablets?

Yes, the medicine is supplied in multiple strengths and forms. These include oral tablets of 25 mg and 100 mg. It is also available as an oral solution/drops and as a sterile solution for injection.

Q: How long does the effect of one dose of Sinogan last?

Levomepromazine has a long duration of action. Pharmacokinetic studies have reported that the biological half-life of the drug in the body can vary widely, generally ranging from approximately 16.5 hours to over 77 hours.

Q: Is it normal to feel a little dizzy when first starting Sinogan?

Postural hypotension (low blood pressure when standing up) is listed as a common side effect in official information. This can frequently be experienced as dizziness or faintness. This effect is often reported as being more noticeable when starting treatment or following a dose increase.

Q: Can Sinogan affect my ability to drive or operate machinery?

Official regulatory information warns that levomepromazine may cause side effects such as drowsiness, disorientation, confusion, or low blood pressure. These effects may impair a person's ability to drive or operate machinery.

Q: Why does the packaging warn about sun sensitivity?

Regulatory patient information notes that levomepromazine can make the skin more sensitive to the effects of the sun (photosensitivity). Official documentation notes this risk and emphasizes the importance of taking precautions to protect the skin from sunlight while using this medication.

Q: Can high temperatures affect the use of Sinogan?

Official documentation notes that antipsychotic agents, including levomepromazine, can potentially disrupt the body's ability to regulate its temperature. Caution is therefore advised for patients who may be exposed to temperature extremes, including very hot or very cold conditions.

Q: Can Sinogan be taken with common pain relievers like paracetamol?

Regulatory documents do not specifically list every single over-the-counter medication. However, the drug is known to be a strong inhibitor of the CYP2D6 liver enzyme. This action has the potential to increase the concentration of other drugs in the body that rely on that enzyme for metabolism.

Q: Does Sinogan interact with common cold or flu medicines?

Official warnings state that levomepromazine can intensify the effects of central nervous system (CNS) depressants. This includes ingredients found in many common cold or flu medicines, such as opioid cough relievers. Combining these may increase the risk of side effects like drowsiness or sedation.

Q: How does Sinogan interact with medicines for depression?

Levomepromazine is documented as a potent inhibitor of the CYP2D6 enzyme in the liver. This effect may lead to increased blood concentrations of other medicines, including some common medicines used to treat depression that are metabolized by this enzyme.

Q: Why do official documents mention 'risk of sudden death' with this type of medicine?

Official documentation notes that levomepromazine may cause a change in heart rhythm called QT prolongation, which can rarely lead to a serious and potentially fatal irregular heartbeat (Torsades de Pointes). This risk is increased in people who have pre-existing cardiac disease.

Q: Can Sinogan affect my blood sugar?

Yes, official documentation states that high blood sugar (hyperglycemia) or difficulty processing glucose has been reported in patients taking levomepromazine. Regulatory guidance notes appropriate blood sugar monitoring is necessary for patients with or at risk of developing diabetes.

Q: What are the signs of a serious reaction to Sinogan?

Serious adverse reactions like Neuroleptic Malignant Syndrome (NMS) may be indicated by symptoms such as fever, muscle stiffness, severe confusion, and heavy sweating. Official safety information mentions that signs of serious issues with blood or liver function may include easy bleeding, bruising, or yellowing of the skin and eyes.

Q: What is the link between Sinogan and seizures?

Official regulatory information notes that levomepromazine may lower the body’s epileptic threshold, which means it may increase the risk of seizures. For this reason, both seizures and convulsions are listed as potential adverse reactions affecting the nervous system.

Q: What kind of monitoring is usually required when taking Sinogan?

Official guidance states that monitoring of the complete blood count and ECG (a heart tracing) may be necessary, especially if a patient has existing risk factors for heart rhythm changes. Appropriate blood sugar monitoring is also noted as necessary for patients with or at risk of diabetes.

Q: Are there any known long-term effects of taking Sinogan?

Long-term exposure to the drug is associated with the risk of developing involuntary movements known as tardive dyskinesia. Regulatory adverse reaction reports also note that long-term use may involve changes to the lens and cornea of the eye.

Q: What is the difference between Sinogan and chlorpromazine?

Both levomepromazine (Sinogan) and chlorpromazine are classified as phenothiazine neuroleptics. Research has compared the two and noted differences in their side-effect profiles. For instance, levomepromazine was observed to be associated with less risk of certain movement disorders when compared to some other similar agents.

Q: How is Sinogan's use studied in children?

Official prescribing information specifies that the medicine is generally restricted or contraindicated in children under 18 years of age for some uses. The regulatory guidance for permitted paediatric use emphasizes that the total daily oral dose must be strictly limited not to exceed 37.5 mg.

Q: Do studies show Sinogan is effective for anxiety symptoms?

Yes, official documents note that levomepromazine has anxiolytic (anti-anxiety) properties. It is mentioned in the context of treating anxiety disorders, confusion, and delirium.

Q: Do researchers look into combining Sinogan with other treatments?

Studies have examined the use of levomepromazine as an adjunct (additional) therapy alongside other treatments. For example, research has looked into combining it with other sedative drugs to help manage patients requiring sedation in intensive care settings.

Q: Is 'Sinogan' the same name used for this drug in every country?

No, Sinogan is the trade name used in certain countries. The active ingredient is known globally by the generic name, Levomepromazine. It is marketed internationally under several other brand names, such as Tisercin and Levomentis.

Q: What happens if Sinogan is stopped suddenly?

Official documentation does not provide details on the specific effects of stopping the medicine suddenly. However, as is common with this class of medicine, regulatory guidance often notes that a gradual dose reduction is necessary when treatment is being concluded.

Q: Is there research on Sinogan use in older adults?

While the core research evidence section does not summarize specific trials in older adults, official regulatory warnings are provided for this population. These warnings note that older adults, especially those with dementia, may have an increased risk of adverse events like hypotension or cerebrovascular events (stroke). For this reason, the prescribing information documents the requirement for a lower initial dosage.

Official Storage and Disposal Requirements

Regulatory documents outline specific mandatory conditions for storing and disposing of Sinogan (levomepromazine) to ensure stability and environmental protection.

Storage Component	Requirement
Environmental Protection	Store in a cool, dry place and protect from light, avoiding direct sunlight exposure.
Container & Safety	Keep the medicine in its original container with the lid tightly closed. It must be stored out of the reach of children and secured.
In-Use Stability	The oral solution has a stability period and must be discarded within 3 months of opening.
Disposal Rules	Do not dispose of in household trash, down the drain, or release to the environment. Unused or expired medication must be returned to a pharmacy or an authorized collection point for safe, controlled disposal, in compliance with applicable hazardous waste regulations.